Accordingly, we designed the ASTEROID trial (A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden) to examine the effects of high-intensity statin therapy on IVUS-derived measures of coronary disease progression. Rosuvastatin is the most recently ...
Medicare beneficiaries aged 66 to 75 years (n = 29 932) and older than 75 years (n = 27 956) hospitalized for myocardial infarction between 2007 and 2012 who filled a high-intensity statin prescription (atorvastatin, 40-80 mg, and rosuvastatin, 20-40 mg) within 30 days of...
Reducing the dose from a high-intensity statin to a moderate-intensity statin may modulate the side effects of a high-intensity statin, while adding ezetimibe to a moderate-intensity statin can maintain the LDL-C lowering capacity similar to a high-intensity statin. Adding ezetimibe to low or ...
Statin use was defined as the first prescription of statins on or after the index date. According to the British NICE guideline,11 high-intensity statin use was defined as atorvas- tatin ≥20 mg/day, rosuvastatin ≥10 mg/day, and simvastatin 80 mg/day, medium-intensity as atorvastatin 10...
Adverse events were infrequent and similar to other statin trials. Very high-intensity statin therapy using rosuvastatin 40 mg/d achieved an average LDL-C of 60.8 mg/dL and increased HDL-C by 14.7%, resulting in significant regression of atherosclerosis for all 3 prespecified IVUS measures of ...
All the patients were candidates for high-intensity statin therapy. The participants were either predisposed to or already had atherosclerotic cardiovascular disease (ASCVD). Approximately two-thirds (62%) of the subjects were on low-dose aspirin as a prophylactic therapy for CVD events. None of ...
Finally, they studied the effect of different doses within the high-intensity statin group. Patients treated with the maximum dose of statins were 10 percent more likely to survive than patients on submaximal doses. "This suggests to practitioners that instead of starting a patient on a low dos...
However, of those on high-intensity statin, 25% remained on insufficient statin dosage. Conclusion Switch to high-intensity statins and use of ezetimibe and PCSK9i was low in chronic ASCVD patients. Even though statin intake was high in high-risk patients, target levels were still not reached...
5 Patients were treated with rosuvastatin, 10 mg, or atorvastatin, 20 mg, for the moderate-intensity statin therapy and rosuvastatin, 20 mg, or atorvastatin, 40 mg, for the high-intensity statin therapy. In the treat-to-target group, the target LDL-C level chosen was the lowest recomm...
Patients were randomized to receive biweekly subcutaneous alirocumab (150 mg; n = 148) or placebo (n = 152), initiated less than 24 hours after urgent percutaneous coronary intervention of the culprit lesion, for 52 weeks in addition to high-intensity statin therapy (rosuvastatin, 20 ...